

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-18 (cancelled).

Claim 19 (New): A method of preventing or reducing immune coagulation associated with fgl2 expression comprising administering an effective amount of an inhibitor of LF-A1 gene or protein to an animal in need thereof.

Claim 20 (New): The method according to claim 19 wherein the animal is infected with a hepatitis virus.

Claim 21 (New): The method of claim 20 wherein the hepatitis virus is selected from the group consisting of MHV-3 and MHV-A59.

Claim 22 (New): The method according to claim 19 wherein the inhibitor inhibits the LF-A1 protein and is an antisense oligonucleotide sequence that comprises a sequence complementary to the fgl-2 promoter region of the animal or a portion of said fgl-2 promoter region effective in inhibiting LF-A1 binding to the LF-A1 binding element of the promoter region of fgl-2.

Claim 23 (New): The method according to claim 22 wherein the oligonucleotide sequence comprises at least 8 nucleotides that is complementary to an 8 nucleotide consecutive sequence of the fgl-2 promoter region.

Claim 24 (New): The method according to claim 22 wherein the fgl-2 promoter region comprises the nucleotide sequence 957 to 1023 of SEQ. ID. NO. 1 and the LF-A1 binding element comprises the nucleotide sequence 997 to 1004 of SEQ. ID. NO. 1.

Claim 25 (New): The method of claim 24 wherein the oligonucleotide sequence comprises a sequence that is complementary to the LF-A1 binding element of the fgl-2 promoter region.

Claim 26 (New): The method according to claim 22 wherein the inhibitor consists of an oligonucleotide sequence complementary to the fgl-2 promoter region of the animal.

Claim 27 (New): The method according to claim 26 wherein the oligonucleotide sequence complementary to the fgl-2 promoter region of the animal is complementary to the nucleotide sequence 957 to 1023 of SEQ. ID. NO. 1.

Claim 28 (New): The method according to claim 22 wherein the oligonucleotide sequence consists of 8 nucleotides that is complementary to an 8 nucleotide consecutive sequence selected from the nucleotide sequence 957 to 1023 of SEQ. ID. NO. 1.

Claim 29 (New): The method according to claim 22 wherein the oligonucleotide sequence consists of a sequence that is complementary to the LF-A1 binding element of the promoter region of the fgl-2 gene.

Claim 30 (New): The method according to claim 29, wherein the LF-A1 binding element of the fgl-2 promoter region is nucleotide sequence 997 to 1004 of SEQ. ID. NO. 1.

Claim 31 (New): The method of claim 19 wherein the inhibitor is an inhibitor of the LF-A1 gene.

Claim 32 (New): The method of claim 31 wherein the inhibitor is an antisense oligonucleotide sequence comprising a sequence complementary to a nucleic acid sequence from the LF-A1 gene.

Please replace claim pages 46-48 currently of record with the above new claims 19-32 as claim pages 52-53.